Company / Cash & Equivalents
PROCEPT BioRobotics Corp Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$286.5M
FY2025
5-year range
$221.9M / $333.7M
FY2021-FY2025
Trend
-14.1%
vs FY2024
Sector context
#65 of 148
Health Care
What the data says
At $287M, PROCEPT BioRobotics Corp's cash & equivalents ranks #65 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 6 years, ranging from $100M in FY2020 to $334M in FY2024.
Based on SEC 10-K filings.
$287M in FY2025 with a 5-year CAGR of +23.4%.
Improved from $257M to $287M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- +23.4%
- 10-Year CAGR
- -
Sector benchmark
#65 of 148 in Health CareTop 44% of 148This company $286.5M Sector average $1.2B
▼
-76.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.4%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 14.1% year-over-year.
- Ranks #65 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $286.5M | -14.1% |
| FY2024 | $333.7M | +29.7% |
| FY2023 | $257.2M | +15.9% |
| FY2022 | $221.9M | -27.1% |
| FY2021 | $304.3M | +203.9% |
| FY2020 | $100.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026